Nationwide Fund Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Nationwide Fund Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-69	Closed	-$24K	–	3280
2017 Q1	$24K	Hold	69	–	–	﹤0.01%	3073
2016 Q4	$24K	Hold	69	–	–	﹤0.01%	3076
2016 Q3	$28K	Hold	69	–	–	﹤0.01%	3099
2016 Q2	$41K	Buy	+69	New	+$41.9K	﹤0.01%	3100
2014 Q2	–	Sell	-69	Closed	-$372K	–	3393
2014 Q1	$372K	Buy	+69	New	+$326K	﹤0.01%	2199

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

Nationwide Fund Advisors's EIGR Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2017, closing a stake of 69 shares — an estimated $24K sold.

Nationwide Fund Advisors first reported a position in EIGR in Q1 2014 and held it in 5 quarters. The position peaked at $372K in Q1 2014. 39 funds tracked by Wall St. Rank hold EIGR as of Q2 2017.

Nationwide Fund Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 69 Eiger BioPharmaceuticals, Inc. shares in Q2 2017, an estimated $24K.
Nationwide Fund Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 5 quarters.
Nationwide Fund Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $372K in Q1 2014.
39 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.